Details

Autor(en) / Beteiligte

• McBride, Ali
• Brokars, John
• Reddy, Sheila Reiss
• Chang, Eunice
• Tarbox, Marian H.
• LeBlanc, Thomas W.

Titel

An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy

Ist Teil von

• Acta haematologica, 2023-08, Vol.146 (4), p.259-267

Ort / Verlag

Basel, Switzerland

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Introduction: Treatment with dasatinib for chronic myeloid leukemia (CML) has been associated with development of pleural effusion; however, data regarding its optimal management are limited. We examined treatment patterns and healthcare resource utilization (HCRU) and costs among patients with CML treated with dasatinib who experienced a subsequent pleural effusion. Methods: Adults with CML and ≥1 pharmacy claim for dasatinib in 2015–2018 who experienced pleural effusion after dasatinib were identified using data from claims databases. Results: Overall, 123 patients were eligible. After 1 year, of the 38.2% of patients with a dose modification, 72.3% did not switch treatment; among these patients, 70.6% continued treatment. Among patients with a stable dose after pleural effusion (61.8%), 57.9% later switched to another TKI. The mean (SD) duration of dasatinib treatment after pleural effusion was 262.0 (124.0) days for patients with a dose modification versus 149.1 (155.2) days for those with a stable dose (p < 0.001). HCRU and costs were similar between groups. Conclusion: Dasatinib dose modification after pleural effusion was not always required; however, patients with dose modifications continued therapy for a longer duration with a lower rate of switching to another TKI versus patients who remained on a stable dose.